logo
Plus   Neg
Share
Email

Foxconn Unit To Buy Belkin Intl. For $866 Mln

Foxconn Interconnect Technology Limited, carrying on business in Hong Kong as FIT Hon Teng Limited, agreed to acquire U.S. consumer electronics maker Belkin International for $866 million in cash, by way of merger.

In a filing on Tuesday, FIT Hon Teng, a unit of Foxconn Technology Group, revealed that upon completion of the merger, Belkin will become a direct wholly-owned subsidiary of the Company. The acquired business and its subsidiaries will be accounted for as subsidiaries in the Company's financial statements.

Belkin, a california-based manufacturer of Wi-Fi routers, mobile device chargers and keyboards, with over 700 patents, generated sales of about $789 million in the fiscal year ended Sept. 30.

FIT said it expects synergies to be achieved from the Merger through mutual leverage of customer channels and sales networks as well as technological and production capabilities.

FIT also anticipates that formation of a new "smart home" business, by combining the existing Linksys and Wemo businesses and related assets, will also help achieve synergies in the Group's businesses.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3... Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor.
Follow RTT
>